2023年第1版NCCN小细胞肺癌临床实践指南解读  

Interpretation of NCCN clinical practice guidelines in small cell lung cancer(Version 1.2023)

作　　者：张爽[1] 吴洪芬[2] 董莹[3] 程颖[1] Zhang Shuang;Wu Hongfen;Dong Ying;Cheng Ying(The First Department of Thoracic Oncology,Jilin Cancer Hospital,Changchun 130000,China;The Fifth Department of Radiotherapy,Jilin Cancer Hospital,Changchun 130000,China;The Third Department of Radiotherapy,Jilin Cancer Hospital,Changchun 130000,China)

机构地区：[1]吉林省肿瘤医院胸部肿瘤内一科,吉林长春130000 [2]吉林省肿瘤医院放疗五科,吉林长春130000 [3]吉林省肿瘤医院放疗三科,吉林长春130000

出　　处：《实用肿瘤杂志》2022年第6期485-489,共5页Journal of Practical Oncology

基　　金：吉林省重大疾病防治重大科技专项项目(20210303002SF)。

摘　　要：2023年第1版NCCN小细胞肺癌(small cell lung cancer,SCLC)临床实践指南主要对接受手术治疗的局限期SCLC进行预防性脑照射的人群进行了更加明确的规定,增添了局限期SCLC胸部放疗最新的研究进展,对>4个月生存的部分脑转移SCLC海马保护的全脑放疗给予了推荐,重新界定了铂类治疗再挑战的人群。本文将对以上更新内容进行介绍和解读。NCCN clinical guidelines for small cell lung cancer(SCLC)(Version 1.2023)mainly provide more explicit provisions for pa-tients requiring prophylactic cranial irradiation(PCI)for limited-stage SCLC(LS-SCLC)undergoing surgical treatment,add the latest re-search progress of thoracic radiotherapy for LS-SCLC,recommend hippocampal-sparing whole-brain radiotherapy for SCLC patients with partial brain metastasis surviving more than 4 months,and redefine suitable patients for platinum rechallenge.This article will introduce and interpret the above updates.

关 键 词：小细胞肺癌 放射治疗 预防性脑照射 化疗 

分 类 号：R734.2[医药卫生—肿瘤]